Investors
Read Our Most Recent Shareholder Letter
Company Overview
Investor Presentation
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19
SAN DIEGO, August 5, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development, patent filing and Emergency...
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests SAN DIEGO – July 23, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare...
AXIM® Biotechnologies Welcomes Former Secretary of Veterans Affairs Peter O’Rourke to Company’s Board of Directors
SAN DIEGO, July 21, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological and COVID-19 research, announced today it has welcomed Former...
Latest Annual Filing
Fiscal Year Ended Dec 31, 2019
Investor Contact Information
Company
AXIM Biotechnologies, Inc.
: 6191 Cornerstone Court, E., Suite 114, San Diego, CA 92121
T: +1 858 923-4422
Investor Relations
T:
Investors@aximbiotech.com
Transfer Agent
Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com